Gamco Investors INC. ET AL Sells 31,700 Shares of Bausch Health Cos Inc. $BHC

Gamco Investors INC. ET AL reduced its holdings in Bausch Health Cos Inc. (NYSE:BHC) by 2.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,043,441 shares of the company’s stock after selling 31,700 shares during the quarter. Gamco Investors INC. ET AL’s holdings in Bausch Health Cos were worth $6,751,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Vanguard Group Inc. raised its position in Bausch Health Cos by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 11,746,480 shares of the company’s stock valued at $76,152,000 after purchasing an additional 61,621 shares during the last quarter. Maple Rock Capital Partners Inc. increased its stake in shares of Bausch Health Cos by 156.7% in the fourth quarter. Maple Rock Capital Partners Inc. now owns 5,300,000 shares of the company’s stock valued at $42,718,000 after buying an additional 3,235,100 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Bausch Health Cos by 3.0% in the fourth quarter. Dimensional Fund Advisors LP now owns 3,113,107 shares of the company’s stock valued at $25,089,000 after buying an additional 90,166 shares during the last quarter. Compass Rose Asset Management LP lifted its position in Bausch Health Cos by 366.7% during the 4th quarter. Compass Rose Asset Management LP now owns 2,100,000 shares of the company’s stock worth $16,926,000 after buying an additional 1,650,000 shares in the last quarter. Finally, Private Management Group Inc. lifted its position in Bausch Health Cos by 13.8% during the 1st quarter. Private Management Group Inc. now owns 1,439,426 shares of the company’s stock worth $9,313,000 after buying an additional 174,176 shares in the last quarter. 78.65% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

BHC has been the subject of several research reports. Wall Street Zen upgraded shares of Bausch Health Cos from a “hold” rating to a “buy” rating in a research report on Saturday, August 2nd. Royal Bank Of Canada increased their price target on shares of Bausch Health Cos from $8.50 to $10.00 and gave the company a “sector perform” rating in a research note on Friday, May 2nd. Three equities research analysts have rated the stock with a Hold rating, According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $9.00.

Bausch Health Cos Stock Performance

Shares of Bausch Health Cos stock opened at $7.28 on Thursday. The firm has a fifty day moving average of $6.68 and a two-hundred day moving average of $6.05. The company has a debt-to-equity ratio of 141.90, a quick ratio of 0.98 and a current ratio of 1.31. The stock has a market capitalization of $2.69 billion, a price-to-earnings ratio of 27.98 and a beta of 0.41. Bausch Health Cos Inc. has a 52 week low of $4.25 and a 52 week high of $9.85.

Bausch Health Cos (NYSE:BHC) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.97 by ($0.07). Bausch Health Cos had a negative return on equity of 852.36% and a net margin of 0.99%.The company had revenue of $2.57 billion during the quarter, compared to the consensus estimate of $2.47 billion. Bausch Health Cos has set its FY 2025 guidance at EPS. As a group, equities research analysts predict that Bausch Health Cos Inc. will post 4.41 EPS for the current year.

Insider Transactions at Bausch Health Cos

In related news, Director John Paulson bought 34,721,118 shares of the firm’s stock in a transaction dated Thursday, August 14th. The stock was bought at an average cost of $9.00 per share, for a total transaction of $312,490,062.00. Following the transaction, the director owned 70,755,869 shares of the company’s stock, valued at $636,802,821. This represents a 96.35% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders bought a total of 44,316,834 shares of company stock worth $369,628,560 in the last quarter. 8.05% of the stock is currently owned by company insiders.

About Bausch Health Cos

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.